Katayoun Jessen

This inventor holds 8 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Oncternal Therapeutics, Inc., Intellikine LLC, Cytovia, Inc.. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katayoun Jessen. Retrieved from https://idiyas.com/inventor/katayoun-jessen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 4)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 15(Granted Patents)

Company Filing History:

4 out of 16

Oncternal Therapeutics, Inc.

Years Active: 2009-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12161626 - Uses of indolinone compounds (2024-12-10),

2. 11285132 - Uses of indolinone compounds (2022-03-29),

3. 10646470 - Uses of indolinone compounds (2020-05-12),

4. 10172858 - Combination pharmaceutical compositions and uses thereof (2019-01-08),

5. 10159660 - Uses of indolinone compounds (2018-12-25),

6. 9682141 - Combination of kinase inhibitors and uses thereof (2017-06-20),

7. 9295673 - Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof (2016-03-29),

8. 7592143 - Methods of treating diseases responsive to induction of apoptosis and screening assays (2009-09-22),

Title: The Innovative Mind of Katayoun Jessen: Revolutionizing Cancer Treatments in San Diego, CA

Introduction:

Katayoun Jessen, a prolific inventor based in the vibrant city of San Diego, CA, is making significant strides in the field of oncology with his groundbreaking patented inventions.

Latest Patents:

With an impressive portfolio of 7 patents, Katayoun Jessen's latest inventions focus on the uses of indolinone compounds in treating acute myeloid leukemia and diffuse large B-cell lymphoma. His methods and compositions involving combinations of venetoclax and indolinone derivatives showcase his commitment to advancing cancer therapies.

Career Highlights:

Having worked with notable companies such as Oncternal Therapeutics, Inc. and Intellikine LLC, Katayoun Jessen has honed his skills and expertise in the biotechnology industry. His innovative approach to drug development has garnered attention and accolades in the scientific community.

Collaborations:

Katayoun Jessen has collaborated with esteemed coworkers such as Brian Lannutti and James Bradley Breitmeyer, pooling their knowledge and skills to push the boundaries of cancer research and treatment. Their collective efforts have led to significant advancements in the field.

Conclusion:

In conclusion, Katayoun Jessen's dedication to innovation and his unwavering commitment to improving cancer treatment are truly commendable. His patents serve as a testament to his ingenuity and passion for making a positive impact in the fight against cancer. San Diego, CA, can proudly claim Katayoun Jessen as one of its visionary inventors shaping the future of healthcare.

Profile summary based on public USPTO records.